THRX News 26.47 Theravance (THRX)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Theravance (THRX) 26.47 $THRX

In Case You Missed It: GlaxoSmithKline Just Had a Phenomenal Week!
Sean Williams, The Motley Fool - Motley Fool - 41 mins ago
It may have been a holiday-shortened week, but global pharmaceutical giant GlaxoSmithKline packed quite the punch with four positive news events bound to excite even the most skeptical Glaxo shareholders. Of course, Glaxo's week was also marred...

Theravance to Report First Quarter 2014 Financial Results on May 6, 2014
Marketwire - Tue Apr 15, 3:06PM CDT
Theravance, Inc. (NASDAQ: THRX) announced today that it will release financial results for the period ended March 31, 2014 after market close on Tuesday, May 6, 2014.

Theravance Set to Possibly Rebound After Yesterday's Selloff of 2.86%
Comtex SmarTrend(R) - Mon Apr 14, 5:54PM CDT
Theravance (NASDAQ:THRX) traded in a range yesterday that spanned from a low of $26.71 to a high of $28.77. Yesterday, the shares fell 2.9%, which took the trading range below the 3-day low of $27.34 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Theravance Shares Down 19.2% Since SmarTrend's Sell Call (THRX)
Comtex SmarTrend(R) - Thu Apr 10, 5:08PM CDT
SmarTrend identified a Downtrend for Theravance (NASDAQ:THRX) on March 7th, 2014 at $34.65. In approximately 1 month, Theravance has returned 19.16% as of today's recent price of $28.01.

Theravance Announces Initiation of Phase 2b Study With TD-4208, an Investigational LAMA for the Treatment of COPD
Marketwire - Thu Apr 10, 3:05PM CDT
Theravance, Inc. (NASDAQ: THRX) announced the initiation of the dose-ranging Phase 2b Study 0117 with TD-4208 as a nebulized aqueous solution in patients with moderate to severe chronic obstructive pulmonary disease (COPD). TD-4208 is an investigational inhaled long-acting muscarinic antagonist (LAMA), discovered using Theravance's multivalent approach to drug design.

Biotech Stocks Coverage -- Research on Seattle Genetics, Theravance, Neurocrine Biosciences, and MiMedx
PR Newswire - Thu Apr 10, 11:30AM CDT
On Wednesday, April 09, 2014, the NASDAQ Composite ended at 4,183.90, up 1.72%, the Dow Jones Industrial Average advanced 1.11% to 16,437.18, and the S&P 500 closed at 1,872.18, up 1.09%. The gains were broad based as eight out of 10 sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 673.27, up 2.11%, and the same has advanced 2.86% in the last three months. Investor-Edge has initiated coverage on the following equities: Seattle Genetics Inc. (NASDAQ: SGEN), Theravance Inc. (NASDAQ: THRX), Neurocrine Biosciences Inc. (NASDAQ: NBIX) and MiMedx Group Inc. (NASDAQ: MDXG). Free technical research on SGEN, THRX, NBIX and MDXG can be downloaded upon signing up at:

Downtrend Call Working As Theravance Stock Falls 13.9% (THRX)
Comtex SmarTrend(R) - Thu Apr 03, 11:20AM CDT
SmarTrend identified a Downtrend for Theravance (NASDAQ:THRX) on March 7th, 2014 at $34.65. In approximately 4 weeks, Theravance has returned 13.94% as of today's recent price of $29.82.

Healthcare Companies Announce Awards, Partnerships, Milestone Payments, and Conference Schedules - Analyst Notes on Inovio, LifePoint, Mallinckrodt, Ligand, and Theravance
PR Newswire - Wed Apr 02, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Inovio Pharmaceuticals, Inc. (NYSEMKT: INO), LifePoint Hospitals Inc. (NASDAQ: LPNT), Mallinckrodt plc (NYSE: MNK), Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), and Theravance Inc. (NASDAQ: THRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Theravance Appoints Kevin Kwok, Head of Talent Acquisition and Strategy
Marketwire - Tue Apr 01, 3:05PM CDT
Theravance, Inc. (the "Company" (NASDAQ: THRX) announced today the appointment of Kevin Kwok as Head of Talent Acquisition and Strategy. Dr. Kwok will be responsible for leading the Company's efforts in talent acquisition and talent management and implementation of the strategies in these areas across the organization.

Is There A Good Explanation For Higher Returns In Women-run Funds?
at The Street - Mon Mar 31, 5:42PM CDT
James Dennin, Kapitall: Women-run funds outperformed last year. Is there a good explanation for this or are women just better?a���� This [...]

Big Pharma's Not-So-Hidden Secret to Success
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 27, 11:05AM CDT
The past week may have been a bit of a bumpy ride for the pharmaceutical and biotech sector following congressional testimony that highlighted the rising cost of branded drugs, but it represents nothing more than a tiny hurdle in what's been an...

Theravance to Present at the 13th Annual Needham Healthcare Conference
Marketwire - Wed Mar 26, 3:05PM CDT
Theravance, Inc. (NASDAQ: THRX) announced today that Michael W. Aguiar, Theravance's Senior Vice President and Chief Financial Officer, is scheduled to present at the 13th Annual Needham Healthcare Conference on Wednesday, April 9, 2014, at 9:20 a.m. EDT. The conference will be held from April 8-9, 2014 at The Westin New York Grand Central Hotel, New York, NY.

1 More Promising Asthma Drug by GlaxoSmithKline
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 19, 5:30PM CDT
No one has a bigger presence in asthma than GlaxoSmithKline . The company's Advair, a treatment for chronic asthma, generated over $4 billion in sales in the U.S. and more than $8 billion world wide last year.  Advair is the best selling drug in...

Glaxo/Theravance Update on COPD Drugs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 18, 5:30PM CDT
GlaxoSmithKline and partner Theravance announced encouraging data from three phase III studies on Anoro Ellipta.

Update on Glaxo's Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 17, 12:53PM CDT
GlaxoSmithKline announced positive data from two phase III studies on mepolizumab.

GSK and Theravance Announce Positive Results From Studies Comparing ANORO(TM) ELLIPTA(TM) With SERETIDE(R) DISKUS(R) and ADVAIR(R) DISKUS(R) in Patients With COPD
Marketwire - Fri Mar 14, 7:01AM CDT
GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced positive results from three phase III studies. Two studies comparing the efficacy and safety of the combination anticholinergic / long-acting beta2-adrenergic agonist, Anoro(TM) Ellipta(TM) (umeclidinium/vilanterol, 'UMEC/VI' with inhaled corticosteroid / long-acting beta2-adrenergic agonist combination, Advair(R) Diskus (R) (fluticasone propionate/salmeterol 'FSC 250/50' and the third comparing the efficacy and safety of Anoro Ellipta with Seretide(R) Diskus(R) 'FSC 500/50' in patients with chronic obstructive pulmonary disease (COPD) and no history of moderate to severe COPD exacerbations in the last year.

Patient Recruitment Completes in Landmark RELVAR(R)/BREO(R) ELLIPTA(R) Study to Understand Mortality and MorbidITy (SUMMIT) in COPD
Marketwire - Thu Mar 13, 7:02AM CDT
GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that recruitment of patients into the "Study to Understand Mortality and MorbidITy", known as SUMMIT, has completed enrolment. The aim of this study, which has now enrolled approximately 16,000 patients, is to determine the impact of Relvar(R)/Breo(R) Ellipta(R) (fluticasone furoate 'FF'/vilanterol 'VI' on all cause mortality amongst patients with moderate chronic obstructive pulmonary disease (COPD) who have cardiovascular disease (CVD) or are at increased risk for CVD.

Financial Results, Clinical Study Updates, Clinical Trial Results, Business Spin-Offs, and New Joint Ventures - Analyst Notes on ARIAD, NewLink, Puma Biotechnology, Theravance, and Ohr Pharmaceutical
PR Newswire - Wed Mar 12, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), NewLink Genetics Corporation (NASDAQ: NLNK), Puma Biotechnology, Inc. (NYSE: PBYI), Theravance, Inc. (NASDAQ: THRX), and Ohr Pharmaceutical, Inc. (NASDAQ: OHRP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Theravance to Split in Q2 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 11:00AM CST
Theravance will split into two independent companies in the second quarter.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 125

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
PexarBolt's CES Honor Meets a Real Crowdfunding Test

Updated Category News Views 77

A little touchscreen bolted onto a dock would usually make me roll my eyes. This time, Pexar has at least put enough muscle behind the gimmick to deserve a harder look. The PexarBolt Ultra TBT5 Dock was named a CES Innovation Awards 2027 Honoree in Computer Peripherals & Accessories, following an IFA 2026 Innovation Awards honor only two months after its launch. Awards do...

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 116

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
Six LIFE Photographers Bring History Into Florida Focus

Updated Category News Views 72

Seventy photographs can make a pretty loud argument when the historical record has been this lopsided. The Ashley Gibson Barnett Museum of Art at Florida Southern College has brought LIFE: Six Women Photographers to Lakeland, and it deserves more than the usual polite nod given to a traveling museum show. Open since November 14, 2026, and running through March 7, 2027,...

Continue Reading
Simmons Clarifies Texas Loan Exposure, But Risks Remain

Updated Category News Views 87

A $45 million discrepancy is not a rounding error, and Simmons First National has every reason to swat it down hard. The bank says recent reporting overstated financing tied to a Texas multifamily development at $133 million. Its stated total is roughly $88 million, with about $44 million participated to another financial institution. For shareholders in NASDAQ:SFNC, that...

Continue Reading
Greenberg Traurig Adds Privacy Muscle in Denver Office

Updated Category News Views 162

Privacy work used to be the legal department's back-room plumbing; now it can jam an entire product launch. That is why Greenberg Traurig's decision to bring Amber Mednick in as of counsel in Denver deserves more attention than the usual law-firm hiring blurb. This is not a splashy deal, and nobody should pretend one lateral hire rewrites the competitive map. Still, it is...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 32

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
OU's $44.3M Rural Care Plan Targets Oklahoma Care Gaps

Updated Category News Views 100

A Long Drive Is a Brutal Barrier to Care Seventy-five of Oklahoma's 77 counties sit in health professional shortage territory, a figure that ought to stop people cold. It means at least 3,500 patients per provider in those counties. That is not some abstract planning headache. It is the pregnant patient delaying a specialist visit, the family weighing an ambulance ride,...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 82

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 40

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading

Top 5 Most Recently Viewed Articles

Significant Unusual Options Activity Signals Opportunity in GOOGL

Updated Category News Views 97

Analyzing Recent Options Activity for Alphabet Currently, investors are exhibiting a strong bullish sentiment towards Alphabet (NASDAQ: GOOGL), a trend that is capturing the attention of market participants. Recent observations of public options have revealed significant movements in GOOGL, hinting at potential changes ahead. Recent analyses have uncovered 129 unusual...

Continue Reading
Encore and UKG Introduce Innovative Overtime Savings Program

Updated Category News Views 298

Encore and UKG Join Forces for Employee Financial Wellness Encore, a prominent global leader in event technology and production services, has unveiled an innovative ‘Overtime Savings Program’ in collaboration with UKG, a top provider of HR and workforce management solutions. This remarkable initiative aims to empower Encore's frontline workers, allowing them to save...

Continue Reading
Discover Incredible Returns from Texas Pacific Land Investments

Updated Category News Views 160

The Incredible Growth of Texas Pacific Land Corp Texas Pacific Land Corp (NYSE: TPL) has marked its presence in the market with an outstanding performance over the past 15 years. The company has outshone the market median by an impressive 32.71% annually, which translates to a staggering average annual return of 45.46%. With a current market capitalization nearing $20.51...

Continue Reading
Cypherpunk Q2 2026: Zcash Growth Sparks Market Buzz

Updated Category News Views 76

Cypherpunk Technologies' Stellar Q2 Performance Sit tight, folks, because Cypherpunk Technologies just unleashed a financial update that's got the market buzzing. They've reported a staggering net income of $39.4 million for Q2 2026, quite the turnaround from a $16.6 million loss in the same quarter last year. It's a serious win, no doubt pumped up by their fruitful Zcash...

Continue Reading
Exciting Findings from Aicuris’ Clinical Trials of AIC468

Updated Category News Views 182

Encouraging Insights into AIC468 from Clinical Trials Recently, a notable advancement in medical research has emerged from Aicuris Anti-infective Cures AG regarding its novel treatment, AIC468. This drug is an innovative antisense oligonucleotide targeting the BK virus, particularly in kidney transplant recipients. The first-in-human (FIH) Phase 1 trial has provided...

Continue Reading